Ann Arbor, MINCT07282587Now EnrollingIRB Ready

Advanced Pheochromocytoma and Paraganglioma Clinical Trial in Ann Arbor, MI

Access cutting-edge advanced pheochromocytoma and paraganglioma treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.

Sponsored by Jazz Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Ann Arbor location

Preparing your pre-screening questions…

Expert Care in Ann Arbor

Access advanced pheochromocytoma and paraganglioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced pheochromocytoma and paraganglioma treatment provided free

Apply for This Ann Arbor Location

Check if you qualify for this advanced pheochromocytoma and paraganglioma clinical trial in Ann Arbor, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Ann Arbor

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Ann Arbor site if eligible
  4. 4Begin participation

About This Advanced Pheochromocytoma and Paraganglioma Study in Ann Arbor

This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).

Sponsor: Jazz Pharmaceuticals

Who Can Participate

Inclusion Criteria

Has histologically confirmed pheochromocytoma or paraganglioma that is unresectable as determined by the Investigator.
Has failed, is not a candidate for, or has declined standard of care treatment for PCPG. There is no limit on the number of prior systemic therapies.
Must have measurable disease per RECIST v1.1, as assessed by the Investigator.
Has adequately controlled blood pressure defined as blood pressure ≤150/90 mmHg and with no change in antihypertensive medications (for participants with concomitant hypertension) for at least 14 days before the first dose of study treatment.
Is ≥18 years of age.
Is able to swallow oral tablets.
Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2, assessed within 7 days before the first dose of study treatment.
Has laboratory test results meeting the following parameters within 14 days before the first dose of study treatment
Has an expected survival of at least 12 weeks, as predicted by the physician.
Has pharmacologic control of catecholamine-associated symptoms if participant has functional disease.

Exclusion Criteria

Has known hypersensitivity to ONC206 or any excipient used in the ONC206 study treatment formulation.
Has active cardiac disease/condition including any of the following:
Corrected QT interval (QTc) \>480 msec (based on the mean from triplicate electrocardiogram \[ECGs\] performed during Screening).
History of documented congestive heart failure (New York Heart Association function classification III-IV).
Unstable angina, acute myocardial infarction, or arterial bypass or percutaneous transluminal coronary angioplasty within 6 months before the first dose of study treatment.
Has previous exposure to ONC206 or dordaviprone (ONC201) from any source.
Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. Exceptions include participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, or Von Hippel-Lindau disease-associated tumors that do not require immediate surgery or intervention.
Has received any of the following interventions within the specified time periods before the first dose of study treatment or plans to receive any of the following interventions during study participation:
a. Any prior anticancer therapy or investigational agents within 4 weeks or 5 half-lives, whichever is shorter. Note: Denosumab and zoledronic acid are permissible. \*\*i. Any treatment with somatostatin analog or lanreotide within 21 days before the baseline Positron Emission Tomography (PET) scan.
b. Strong cytochrome P450 (CYP) inhibitors within 14 days. c. Strong CYP inducers within 14 days. d. Any radiotherapy within 14 days. e. Any major surgery, open biopsy or significant traumatic injury within 1 month (30 days).
Is pregnant, breastfeeding, or planning to become pregnant while receiving study treatment or within 3 months after the last dose.
Has uncontrolled intercurrent illness or any other medical, psychiatric, or social condition that, in the opinion of the Investigator, may interfere with participant safety or the ability to comply with study requirements.
Has unresolved toxicities from previous locoregional, systemic, or any other therapies, defined as toxicities (other than Grade ≤2 neuropathy or alopecia) not yet resolved to the National Cancer Institute Common Terminology Criteria for Adverse Events Grade ≤1, or baseline and considered clinically significant; consult with Medical Monitor.
Has an active infection that requires systemic therapy.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ann Arbor?

Yes, this clinical trial (NCT07282587) has an active research site in Ann Arbor, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Pheochromocytoma and Paraganglioma Treatment Options in Ann Arbor, MI

If you're searching for advanced pheochromocytoma and paraganglioma treatment options in Ann Arbor, MI, this clinical trial (NCT07282587) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced pheochromocytoma and paraganglioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced pheochromocytoma and paraganglioma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Ann Arbor, MI

See all brain cancer clinical trials recruiting in Ann Arbor — not just this study.

Browse Brain Cancer Trials in Ann Arbor →

Browse More Trials by Condition

Brain Cancer TrialsAlzheimers Disease TrialsRheumatoid Arthritis TrialsPulmonary Hypertension TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Ann Arbor?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Ann Arbor, MI